Work

Supplementary Figure 3 from Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 3. A) Immunostaining with anti-hMSLN antibody in orthotopic KPCdelMsln+hMSLN tumors following LMB-100 treatment. Scale bar = 800 µm. B) IP and orthotopic KPCdelMsln+hMSLN tumors were stained with Maisson Trichrome and percent positive pixels was quantified by image analysis. Each point represents quantification from a separate tumor/animal.

DOI: 10.1158/1535-7163.22521732

Authors: Brendan Hagerty, T. Norene O'Sullivan, Xianyu Zhang, N. Keith Collins, Wendi Custer Lawrence, Laura L. Bassel, Nathan Pate, Jian Xu, Theresa M. Guerin, Serguei Kozlov, Christine Alewine

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362614616

Cites:

Cited by:

Related to: 10